Charlie Kim, Ph.D.

Life Science Executive with experience in general management of a molecular portfolio, cross-functional team leadership, business planning including development of go to market strategies and annual forecasting, and strategic partnering. 

My leadership principles include prioritizing and articulating purpose, exercising focus and discipline in strategy, embodying authenticity and integrity, and practicing empathy.

Advisory Roles

• Aridica Corporation, May 2024 - Present

• ImYoo Inc., May 2024-Present

• Venture Capital (multiple organizations)

Verily | Head of Molecular Science

AUGUST 2015 - MAY 2024,  SOUTH SAN FRANCISCO, CA 

• Oversight of platform innovations such as Immune Profiler and Digital Pathology and cross-functional leadership of product strategy and business planning, including molecular, immunology, computational biology, product, marketing, quality, legal, and business development teams

• R&D partnerships with industry-leading biopharma such as Gilead, Janssen, Allergan, Sosei Heptares, Georgiamune, and Kyverna 

University of California, San Francisco | Assistant Professor

JULY 2011 - AUGUST 2015,  SAN FRANCISCO, CA 

• Tenure-track faculty in Department of Medicine, Division of Experimental Medicine

• Oversight of all aspects of research lab including hiring and training research staff and academic trainees, grant writing, experimental design / conduct / analysis, manuscript preparation, presentation, and lab administration

• Specialization in translational and mouse immunology and genomics

University of California, San Francisco | Postdoc

FEBRUARY 2005 - JUNE 2011,  SAN FRANCISCO, CA

Genomic anaysis of innate immunity to malaria

Mentor: Joe DeRisi

Stanford University | Ph.D. Microbiology & Immunology

AUGUST 1997 - SEPTEMBER 2004,  STANFORD, CA

Molecular/genomic analysis of gene expression during Salmonella disease

Mentor: Stanley Falkow

University of Illinois, Urbana-Champaign | B.S. Biochemistry

AUGUST 1993 - MAY 1997, URBANA, IL

Undergrad thesis: Purification of recombinant Enterococcus faecalis PyrR

Mentor: Robert Switzer

See my full CV or NCBI Bibliography for a comprehensive list

• Leung JM, Wu MJ, Kheradpour P, Chen C, Drake KA, Tong G, Ridaura V, Zisser HC,  Conrad WA, Hudson N, Allen J, Welberry C, Parsy-Kowalska C, Macdonald I, Tapson V, Moy J, DeFilippi C, Rosas I, Basit M, Krishnan JA, Parthasarathy S, Prabhakar BS, Salvatore M, Kim CC. Early immune factors associated with the development of post-acute sequelae of SARS-CoV-2 infection in hospitalized and nonhospitalized individuals. Front Immunol. 2024 Jan 2. doi: 10.3389/fimmu.2024.1348041

• McNeil C, Wong PF, Sridhar N, Wang Y, Santori C, Wu CH, Homyk A, Gutierrez M, Behrooz A, Tiniakos D, Burt A, Pai RK, Tekiela K, Chen PC, Fischer L, Martins EB, Seyedkazemi S, Freedman D, Kim CC, Cimermancic P. An end-to-end platform for digital pathology using hyperspectral autofluorescence microscopy and deep learning based virtual histology. Mod Pathol. 2023 Nov 4; 100377. doi:10.1016/j.modpat.2023.100377

• Drake K, Talantov D, Tong G, Lin J, Verheijden S, Katz S, Leung JM, Yuen B, Krishna V, Wu MJ, Sutherland A, Short S, Kheradpour P, Mumbach M, Franz K, Trifonov V, Lucas M, Merson J*, Kim CC* and the PRESCO Study Group. Multi-omic profiling reveals early immunological indicators of progression to clinically significant COVID-19. Clin Immunol. 2023 Oct 24; 256:109808. doi: 10.1016/j.clim.2023.109808. *Co-authors

• Chen C, Parthasarathy S, Leung JM, Wu MJ, Drake K, Ridaura VK, Zisser HC, Conrad WA, Tapson VF, Moy JN, deFilippi CR, Rosas IO, Prabhakar BS, Basit M, Salvatore M, Krishnan J*, Kim CC*. Early clinical features uncover distinct trajectories in developing Post-acute sequelae of SARS-CoV-2. Front Med. 2023 Oct 16; 10:1227883. doi: 10.3389/fmed.2023.1227883. *Co-authors

• Guo MH, Sama P, LaBarre BA, Lokhande H, Balibalos J, Chu C, Du X, Kheradpour P, Kim CC, Oniskey T, Snyder T, Soghoian DZ, Weiner HL, Chitnis T, Patsopoulos NA. Dissection of multiple sclerosis genetics identifies B and CD4+ T cells as driver cell subsets. Genome Biol. 2022 Jun 7;23(1):127. doi: 10.1186/s13059-022-02694-y